Safety of JAK Inhibitors

Aug 02, 2021, 05:07 PM

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.

Time stamps:

0:47: What do rheumatologists need to know about the recent press release from Pfizer regarding the safety of JAK inhibitors?

2:47: According to analysts, the response to the safety of JAK inhibitors is not surprising. Did you expect this scrutiny in JAK inhibitors?

7:12: What are some of the concerns rheumatologist have in regards to the safety of JAK inhibitors?

9:22: What are your thoughts on prescribing JAK inhibiting drugs to your patients?

11:21: What does this mean for the future of JAK inhibitors?

11:52: Is there anything else you'd like our audience to know before you wrap up?